相关实验视频

Updated: Sep 14, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

特拉斯图祖马布-德鲁克斯坦和放射治疗:Combart前性队列研究的安全性子分析

Edy Ippolito^1,2, Martina Benincasa¹, Francesco Pantano^3,4

¹Research Unit of Radiation Oncology (Medicine and Surgery), Università Campus Bio-Medico di Roma, Rome, Italy.

|July 24, 2025

概括

将放射治疗 (RT) 与Trastuzumab Deruxtecan (T-DXd) 结合使用,在转移性乳腺癌中显示出有前途的安全性. 非血液毒性主要与RT相关,而血液毒性需要对T-DXd影响进行监测.

科学领域:

在瘤学瘤学.
辐射疗法辐射疗法
药理学药理学是指药理学的学科.

背景情况:

转移性乳腺癌 (第四阶段) 提出了独特的治疗挑战.
新的全身疗法,如Trastuzumab Deruxtecan (T-DXd),正在推动医疗保健的发展.
将T-DXd与放射治疗 (RT) 结合使用需要仔细评估安全性.

研究的目的:

在转移性乳腺癌患者中评估同步放射治疗 (RT) 和Trastuzumab Deruxtecan (T-DXd) 的安全性.
识别和分类与RT相关的急性和晚期毒性.
评估并发治疗对无进展生存期的影响.

主要方法:

对预期的COMBART队列的观察分析.
患者接受了传统RT或立体辐射疗法 (SRT) 与T-DXd.同时.
使用NCI CTCAE v5.0对毒性进行分级;主要终点是安全性评估.

主要成果:

40名患者同时接受RT/SRT和T-DXd,治疗了98个病变.
20%的患者出现了急性毒性 (任何级别);3级贫血导致一名患者停止RT治疗.
晚期毒性 (10%) 包括放射性肺炎和放射性死;SBRT治疗患者的PFS2为11.3个月.

结论:

同时的RT和T-DXd在转移性乳腺癌中显示出有希望的安全性.
非血液学毒性主要归因于RT.
血液毒性可能受到T-DXd的影响,需要密切监测.

关键词:

特拉斯图祖马布-德鲁克斯特可以.乳腺癌乳腺癌乳腺癌放射疗法是一种放射治疗.在安全方面,安全是安全的.

更多相关视频

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment

Published on: June 21, 2022

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Hazard Ratio

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...